OREXIGEN THERAPEUTICS INC's ticker is and the CUSIP is 686164AB0. A total of 16 filers reported holding OREXIGEN THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,780,000,000 | -7.3% | 7,500,000 | 0.0% | 0.05% | +11.4% |
| Q3 2017 | $3,000,000,000 | 0.0% | 7,500,000 | 0.0% | 0.04% | -10.2% |
| Q2 2017 | $3,000,000,000 | 0.0% | 7,500,000 | 0.0% | 0.05% | -3.9% |
| Q1 2017 | $3,000,000,000 | -20.0% | 7,500,000 | -50.0% | 0.05% | -29.2% |
| Q4 2016 | $3,750,000,000 | -36.8% | 15,000,000 | -30.0% | 0.07% | -18.2% |
| Q3 2016 | $5,934,000,000 | -29.8% | 21,414,000 | 0.0% | 0.09% | -51.6% |
| Q2 2016 | $8,452,000,000 | -5.8% | 21,414,000 | 0.0% | 0.18% | +10.3% |
| Q1 2016 | $8,975,000,000 | -28.3% | 21,414,000 | +3.6% | 0.16% | -21.8% |
| Q4 2015 | $12,519,000,000 | -6.8% | 20,664,000 | +8.3% | 0.21% | -23.0% |
| Q3 2015 | $13,438,000,000 | -10.0% | 19,075,000 | +18.7% | 0.27% | +5.8% |
| Q2 2015 | $14,928,000,000 | -13.3% | 16,075,000 | +7.2% | 0.26% | -29.6% |
| Q1 2015 | $17,219,000,000 | +79.8% | 15,000,000 | +57.9% | 0.37% | +120.4% |
| Q4 2014 | $9,579,000,000 | – | 9,500,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 20,871,000 | $12,627,000 | 3.02% |
| Telemetry Investments, L.L.C. | 9,426,000 | $5,473,000 | 1.86% |
| Partner Investment Management, L.P. | 437,000 | $261,000 | 0.43% |
| PFM Health Sciences, LP | 16,788,000 | $10,034,000 | 0.30% |
| Verition Fund Management LLC | 2,066,000 | $1,210,000 | 0.23% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 20,664,000 | $12,519,000,000 | 0.21% |
| Cheyne Capital Management (UK) LLP | 500,000 | $298,000 | 0.16% |
| SYMPHONY ASSET MANAGEMENT LLC | 2,244,000 | $1,314,000 | 0.14% |
| WOLVERINE ASSET MANAGEMENT LLC | 6,000,000 | $3,498,000 | 0.08% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,743,000 | $1,030,000 | 0.03% |